Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.
Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2072143. doi: 10.1080/21645515.2022.2072143. Epub 2022 May 19.
In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the disease. Belimumab (BEL), a fully human monoclonal IgG1λ antibody neutralizing soluble B cell activating factor, was approved more than ten years ago as add-on therapy in adults and pediatric patients with a highly active, autoantibody-positive disease despite standard of care (SoC). Recently, the superiority of the addition of BEL to SoC was also demonstrated in LN. In this review, we provide a comprehensive overview of the study landscape, available therapeutic options for SLE (focusing on BEL in renal and non-renal SLE), and new perspectives in the treatment field of this disease. A personalized treatment approach will likely become available with the advent of novel therapeutic agents for SLE and LN.
近年来，系统性红斑狼疮（SLE）患者的治疗和管理进展提高了他们的预期寿命和生活质量。然而，狼疮肾炎（LN）仍然是该疾病的主要危及生命的并发症。贝丽珠单抗（BEL）是一种完全人源化单克隆 IgG1λ 抗体，可中和可溶性 B 细胞激活因子，十多年前被批准作为标准治疗（SoC）的附加疗法，用于治疗成人和儿科患者的高度活跃、自身抗体阳性疾病。最近，BEL 添加到 SoC 在 LN 中也显示出优越性。在这篇综述中，我们全面概述了研究现状、SLE 的可用治疗选择（重点关注 BEL 在肾性和非肾性 SLE 中的应用）以及该疾病治疗领域的新视角。随着 SLE 和 LN 的新型治疗药物的出现，可能会出现个性化的治疗方法。
